These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

114 related items for PubMed ID: 8268127

  • 1. IL-2-dependent induction of G1 cyclins in primary T cells is not blocked by rapamycin or cyclosporin A.
    Turner JM.
    Int Immunol; 1993 Oct; 5(10):1199-209. PubMed ID: 8268127
    [Abstract] [Full Text] [Related]

  • 2. Independent regulation of human D-type cyclin gene expression during G1 phase in primary human T lymphocytes.
    Ajchenbaum F, Ando K, DeCaprio JA, Griffin JD.
    J Biol Chem; 1993 Feb 25; 268(6):4113-9. PubMed ID: 8382693
    [Abstract] [Full Text] [Related]

  • 3. Rapamycin inhibition of interleukin-2-dependent p33cdk2 and p34cdc2 kinase activation in T lymphocytes.
    Morice WG, Wiederrecht G, Brunn GJ, Siekierka JJ, Abraham RT.
    J Biol Chem; 1993 Oct 25; 268(30):22737-45. PubMed ID: 8226784
    [Abstract] [Full Text] [Related]

  • 4. Induction of cell cycle regulatory proteins in anti-immunoglobulin-stimulated mature B lymphocytes.
    Solvason N, Wu WW, Kabra N, Wu X, Lees E, Howard MC.
    J Exp Med; 1996 Aug 01; 184(2):407-17. PubMed ID: 8760794
    [Abstract] [Full Text] [Related]

  • 5. Interleukin-2-mediated elimination of the p27Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin.
    Nourse J, Firpo E, Flanagan WM, Coats S, Polyak K, Lee MH, Massague J, Crabtree GR, Roberts JM.
    Nature; 1994 Dec 08; 372(6506):570-3. PubMed ID: 7990932
    [Abstract] [Full Text] [Related]

  • 6. Distribution of IL-15 receptor alpha-chains on human peripheral blood mononuclear cells and effect of immunosuppressive drugs on receptor expression.
    Chae DW, Nosaka Y, Strom TB, Maslinski W.
    J Immunol; 1996 Oct 01; 157(7):2813-9. PubMed ID: 8816384
    [Abstract] [Full Text] [Related]

  • 7. Rapamycin (sirolimus) inhibits proliferating cell nuclear antigen expression and blocks cell cycle in the G1 phase in human keratinocyte stem cells.
    Javier AF, Bata-Csorgo Z, Ellis CN, Kang S, Voorhees JJ, Cooper KD.
    J Clin Invest; 1997 May 01; 99(9):2094-9. PubMed ID: 9151781
    [Abstract] [Full Text] [Related]

  • 8. Mechanism of action of rapamycin: new insights into the regulation of G1-phase progression in eukaryotic cells.
    Wiederrecht GJ, Sabers CJ, Brunn GJ, Martin MM, Dumont FJ, Abraham RT.
    Prog Cell Cycle Res; 1995 May 01; 1():53-71. PubMed ID: 9552353
    [Abstract] [Full Text] [Related]

  • 9. V3 loop of human immunodeficiency virus type 1 reduces cyclin E expression and induces G1 arrest in interleukin 2-dependent T cells.
    Sakaida H, Kawamata S, Hattori T, Uchiyama T.
    AIDS Res Hum Retroviruses; 1998 Jan 01; 14(1):31-8. PubMed ID: 9453249
    [Abstract] [Full Text] [Related]

  • 10. Rapamycin inhibits human renal epithelial cell proliferation: effect on cyclin D3 mRNA expression and stability.
    Pallet N, Thervet E, Le Corre D, Knebelmann B, Nusbaum P, Tomkiewicz C, Meria P, Flinois JP, Beaune P, Legendre C, Anglicheau D.
    Kidney Int; 2005 Jun 01; 67(6):2422-33. PubMed ID: 15882288
    [Abstract] [Full Text] [Related]

  • 11. Interleukin-2 receptor (CD25) upregulation on human T-lymphocytes: sensitivity to immunosuppressants is defined by the mode of T-lymphocyte activation.
    Ryffel B, Willcocks JL, Brooks N, Woerly G.
    Immunopharmacology; 1995 Sep 01; 30(3):199-207. PubMed ID: 8557519
    [Abstract] [Full Text] [Related]

  • 12. Inhibition of cell cycle progression by rapamycin induces T cell clonal anergy even in the presence of costimulation.
    Powell JD, Lerner CG, Schwartz RH.
    J Immunol; 1999 Mar 01; 162(5):2775-84. PubMed ID: 10072524
    [Abstract] [Full Text] [Related]

  • 13. All-trans retinoic acid stimulates IL-2-mediated proliferation of human T lymphocytes: early induction of cyclin D3.
    Engedal N, Gjevik T, Blomhoff R, Blomhoff HK.
    J Immunol; 2006 Sep 01; 177(5):2851-61. PubMed ID: 16920920
    [Abstract] [Full Text] [Related]

  • 14. Rapamycin blocks cell cycle progression of activated T cells prior to events characteristic of the middle to late G1 phase of the cycle.
    Terada N, Lucas JJ, Szepesi A, Franklin RA, Domenico J, Gelfand EW.
    J Cell Physiol; 1993 Jan 01; 154(1):7-15. PubMed ID: 8419408
    [Abstract] [Full Text] [Related]

  • 15. Expression of cyclins A, D2 and D3 in individual normal mitogen stimulated lymphocytes and in MOLT-4 leukemic cells analyzed by multiparameter flow cytometry.
    Gong J, Bhatia U, Traganos F, Darzynkiewicz Z.
    Leukemia; 1995 May 01; 9(5):893-9. PubMed ID: 7769853
    [Abstract] [Full Text] [Related]

  • 16. Induction of IL-5 expression by IL-2 is resistant to the immunosuppressive agents cyclosporin A and rapamycin.
    Valentine JE, Sewell WA.
    Int Immunol; 1997 Jul 01; 9(7):975-82. PubMed ID: 9237106
    [Abstract] [Full Text] [Related]

  • 17. The RB/p107/p130 phosphorylation pathway is not inhibited in rapamycin-induced G1-prolongation of NIH3T3 cells.
    Chen Y, Knudsen ES, Wang JY.
    Oncogene; 1996 Oct 17; 13(8):1765-71. PubMed ID: 8895523
    [Abstract] [Full Text] [Related]

  • 18. Differential effect of rapamycin and cyclosporin A in proliferation in a murine T cell line expressing either intermediate or high affinity receptor for IL-2.
    Rebollo A, Mérida I, Gómez J, Pitton C, Silva A, Martínez C, García A.
    Cytokine; 1995 Apr 17; 7(3):277-86. PubMed ID: 7543780
    [Abstract] [Full Text] [Related]

  • 19. Rapamycin-induced inhibition of p34cdc2 kinase activation is associated with G1/S-phase growth arrest in T lymphocytes.
    Morice WG, Brunn GJ, Wiederrecht G, Siekierka JJ, Abraham RT.
    J Biol Chem; 1993 Feb 15; 268(5):3734-8. PubMed ID: 8429048
    [Abstract] [Full Text] [Related]

  • 20. Effect of rapamycin on the expression of the IL-2 receptor (CD25).
    Woerly G, Brooks N, Ryffel B.
    Clin Exp Immunol; 1996 Feb 15; 103(2):322-7. PubMed ID: 8565319
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.